Table 1.
Cohort-wise demographic and clinical information.
| Cohort | Number of participants | Diagnosis (EOS/AFP/OTP) | Female N (%) | Mean Age ± SD | EOP specific measures Mean ± SD | Scanner field strength (Tesla) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EOP | HC | EOP | HC | EOP | HC | Age of onseta | Duration of illnessb | IQc | PANSS Neg.d | PANSS Pos.d | CPZe | 3.0 | ||
| ROME | 29 | 14 | 23/1/5 | 8 (27.6) | 8 (57.1) | 16.8 ± 2.0 | 13.6 ± 1.7 | 15.7 ± 2.3 | 1.1 ± 0.9 | NA | 15.9 ± 5.7 | 20.2 ± 7.9 | 375.8 ± 735.7 | 3.0 |
| SCAPS | 34 | 23 | 2/20/12 | 18 (52.9) | 18 (78.3) | 16.4 ± 1.2 | 16.7 ± 1.3 | 15.0 ± 2.0 | 1.5 ± 1.6 | NA | NA | NA | 166.7 ± 146.2 | 3.0 |
| RUND | 22 | 31 | 15/0/7 | 11 (50.0) | 15 (48.4) | 15.9 ± 1.7 | 15.5 ± 1.7 | 14.4 ± 2.0 | 1.9 ± 1.4 | 96.8 ± 14.0 | 11.5 ± 4.8 | 14.3 ± 4.2 | 174.5 ± 226.5 | 1.5 |
| YTOP-1 | 22 | 30 | 15/0/7 | 15 (68.2) | 18 (60.0) | 16.7 ± 1.1 | 16.3 ± 1.3 | 14.6 ± 2.0 | 2.1 ± 1.9 | 102.1 ± 11.8 | 20.5 ± 7.2 | 18.2 ± 3.9 | 136.3 ± 232.9 | 3.0 |
| YTOP-2 | 18 | 40 | 8/2/8 | 15 (83.3) | 21 (52.5) | 16.2 ± 1.2 | 16.1 ± 1.6 | 14.8 ± 1.6 | 1.3 ± 0.8 | 97.4 ± 13.7 | 17.2 ± 6.4 | 15.1 ± 4.8 | 159.7 ± 250.8 | 3.0 |
| KCL-1 | 14 | 15 | 14/0/0 | 4 (28.6) | 6 (40.0) | 16.8 ± 1.4 | 16.2 ± 1.7 | 14.5 ± 2.4 | 2.2 ± 1.6 | 97.4 ± 11.3 | 13.6 ± 3.0 | 10.9 ± 3.8 | NA | 1.5 |
| KCL-2 | 20 | 25 | 6/2/12 | 0 (0) | 0 (0) | 17.0 ± 1.2 | 16.4 ± 1.6 | 16.3 ± 1.4 | 1.1 ± 0.8 | NA | 13.5 ± 6.7 | 15.4 ± 7.1 | NA | 3.0 |
| OXFORD | 44 | 24 | 44/0/0 | 17 (38.6) | 10 (41.7) | 16.3 ± 1.3 | 16.0 ± 1.5 | 14.6 ± 1.6 | 1.8 ± 1.3 | 89.2 ± 15.9 | 16.0 ± 3.2 | 22.4 ± 2.8 | 345.6 ± 236.1 | 3.0 |
| BARCELONA-1 | 48 | 23 | 33/11/4 | 22 (45.8) | 12 (52.2) | 16.3 ± 1.6 | 16.6 ± 1.2 | 15.9 ± 1.6 | 0.5 ± 0.7 | NA | 13.9 ± 6.5 | 21.0 ± 7.0 | 264.1 ± 228.7 | 1.5 |
| BARCELONA-2 | 120 | 78 | 42/64/14 | 60 (50.0) | 48 (61.5) | 16.0 ± 1.5 | 15.7 ± 2.1 | 15.6 ± 1.6 | 0.4 ± 0.5 | NA | 17.1 ± 7.1 | 19.9 ± 6.6 | 257.5 ± 178.2 | 3.0 |
| PAFIP | 17 | 12 | 17/0/0 | 7 (41.2) | 4 (33.3) | 18.0 ± 0.6 | 17.5 ± 1.3 | 17.6 ± 0.6 | 0.4 ± 0.3 | 93.2 ± 14.1 | NA | NA | 185.0 ± 83.0 | 3.0 |
| SRI | 28 | 75 | 0/28/0 | 16 (57.1) | 38 (50.7) | 17.5 ± 1.3 | 16.9 ± 1.8 | 15.4 ± 2.2 | 2.2 ± 2.0 | NA | NA | NA | NA | 3.0 |
| MADRID | 28 | 57 | 26/0/2 | 6 (21.4) | 27 (47.4) | 15.9 ± 1.7 | 12.0 ± 3.2 | NA | NA | NA | NA | NA | NA | 1.5 |
| SYDNEY | 26 | 10 | 11/3/12 | 8 (30.8) | 8 (80.0) | 22.0 ± 4.4 | 18.4 ± 3.2 | 14.7 ± 2.3 | 7.9 ± 4.8 | NA | NA | NA | 276.7 ± 237.6 | 3.0 |
| FEMS | 12 | 12 | 0/12/0 | 2 (16.7) | 3 (25.0) | 19.4 ± 1.2 | 19.8 ± 2.1 | 16.8 ± 1.1 | NA | NA | NA | NA | NA | 3.0 |
| Combined total or mean | 482 | 469 | 256/143/83 | 209 (43.4) | 236 (50.3) | 17.1 | 16.2 | 15.3 | 1.9 | 96.0 | 15.5 | 17.5 | 234.2 | |
EOP early-onset psychosis, EOS early-onset schizophrenia, AFP affective psychosis, OTP other psychosis, HC healthy controls, PANSS Positive and Negative Syndrome Scale, IQ intelligence quotient, CPZ chlorpromazine equivalent medication dose (mg), NA indicates the data was not available.
aAge of onset data is available from 439 patients from 14 cohorts.
bDuration of illness data is available from 427 patients from 13 cohorts.
cIQ data is available from 141 patients from 6 cohorts.
dPANSS data is available from 311 patients from 9 cohorts.
eCPZ data is available from 342 patients from 10 cohorts.